

# 100mg

## Catalog No: Tosedostat



### Available Sizes

**Size:** c21h30n2o6



### Specifications

**CAS No:**

casno

**Formula:**

238750<sup>-77</sup>1

**Pathway:**

Aminopeptidase

**Target:**

Tosedostat is an **aminopeptidase** inhibitor. IC<sub>50</sub> & Target: Aminopeptidase<sup>[1]</sup>  
**In Vitro:** Treatment of HL-60 cells with Tosedostat (CHR-2797) leads to an increase in the secretion of Stanniocalcin 2 (STC2) protein into the growth medium. Increases in *SLC7A11* expression are detectable at 60 nM Tosedostat and as early as 2 h posttreatment. The IC<sub>50</sub>s for inhibition of proliferation by Tosedostat in U-937 and HuT 78 cell lines are 10 nM and >10 μM, respectively. Tosedostat treatment increases expression of amino acid deprivation response (AADR) genes in U-937 cells but not in HuT 78 cells<sup>[1]</sup>. By 24 h with 0.01 μM Tosedostat the mean MCA production is reduced to 77.8% of the untreated control cells; similarly the MCA production is reduced to 51.3% with 1 μM, 38.5% with 5 μM, and 35.3% with 10 μM Tosedostat<sup>[2]</sup>. **In Vivo:** Tosedostat (CHR-2797) is active as an anticancer agent *in vivo* in rodent cancer models, and a dose-response relationship has been shown in two models. The effect of Tosedostat is less apparent when the tumor burden is higher before treatment<sup>[1]</sup>.

**Purity / Grade:**

406.47

**Solubility:**

Launched

**Alternative Names:**

1740

**Observed Molecular Weight:**CHR-2797

---



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!